Literature DB >> 3076761

Immunotherapy of cancer using interleukin 2: current status and future prospects.

S A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3076761     DOI： 10.1016/0167-5699(88)91261-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  57 in total

1.  The antitumour activity of the interferon inducer bropirimine is partially mediated by endogenous tumour necrosis factor alpha.

Authors:  M Scheringa; J N IJzermans; J Jeekel; R L Marquet
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity.

Authors:  D M Finkelstein; R G Miller
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 3.  Immunomodulation following chemotherapy.

Authors:  M Obadina; U Verma; M Hawkins; A Mazumder
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 4.  Local and regional immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

5.  Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells.

Authors:  G Gallagher; F Wilcox; F al-Azzawi
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

6.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.

Authors:  M Suzuki; T Kikuchi; F Takatsuki; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

8.  Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Authors:  Y Tomita; H Watanabe; H Kobayashi; T Nishiyama; S Tsuji; M Fujiwara; S Sato
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.

Authors:  I H Ames; G M Gagne; A M Garcia; P A John; G M Scatorchia; R H Tomar; J G McAfee
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.

Authors:  M Harada; G Matsuzaki; Y Shinomiya; S Kurosawa; O Ito; T Okamoto; M Takenoyama; H Sumitika; Y Nishimura; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.